Date: 2011-06-16
Type of information: Collaboration agreement
Compound: Cell line development services
Company: Cevec (Germany) Catalent Pharma Solutions (USA)
Therapeutic area:
Type agreement: collaboration
Action mechanism:
Disease:
Details: CEVEC Pharmaceuticals, the German developer of a novel, market leading human protein expression system derived from amniocytes, and Catalent Pharma Solutions, a leading global drug development and delivery solutions provider, have announced a joint commercial cell line development service for pharma and biotech customers worldwide. The offering combines the benefits of CEVEC’s human cell line, CAP-Technology, with Catalent’s unique GPEx® (Gene Product Expression) Technology to generate high expressing stable human cell lines in a much shorter timeframe than traditional methods.This collaboration will offer biotech companies developing recombinant proteins and antibodies the advantage of two technologies in one system, enabling them to get a clone candidate in less than 5 months and significantly reducing their time to clinic.
Financial terms: Financial details were not disclosed.
Latest news:
